Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
MK-8876 · 1 trial · 1 indication
The mean change (log10) in HCV ribonucleic acid (RNA) from baseline to Day 7 was determined for each panel of participants.
| Arm | Type | Description |
|---|---|---|
| Panel A: HCV GT3 MK-8876 150 mg | EXPERIMENTAL | Participants infected with HCV GT3 received 150 mg MK-8876 once daily (q.d.) by mouth for 7 days. |
| Panel B: HCV GT3 MK-8876 800 mg | EXPERIMENTAL | Participants infected with HCV GT3 received 800 mg MK-8876 q.d. by mouth for 7 days. |
| Panel E: HCV GT1a MK-8876 800 mg | EXPERIMENTAL | Participants infected with HCV GT1a received 800 mg MK-8876 q.d. by mouth for 7 days. |
| Name | Type | Description |
|---|---|---|
| MK-8876 | DRUG | MK-8876 10 mg or 100 mg tablets taken q.d. by mouth. |
Inclusion Criteria: * is male, or female of non-childbearing potential (non-childbearing potential is defined as postmenopausal without menses for ≥1 year or after medically documented hysterectomy, oophorectomy, or tubal ligation) * agrees to use a medically acceptable method of contraception thro...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Atea Pharmaceuticals, Inc. | AVIR | 2 | PHASE3 | Bemnifosbuvir-Ruzasvir, Sofosbuvir-Velpatasvir |
| Abbott Laboratories | ABT | 2 | - | Undisclosed |
| AbbVie, Inc. | ABBV | 1 | - | Undisclosed |
MK-8876 is an investigational small molecule being developed for the treatment of Hepatitis C. It is currently in Phase 1 clinical development and has been studied in a completed clinical trial involving participants with Hepatitis C infection.
MK-8876 is being developed by Merck & Company, Inc., which is publicly traded under the ticker symbol MRK. The company is conducting clinical research to evaluate the safety, pharmacokinetics, and pharmacodynamics of this investigational drug in Hepatitis C.
MK-8876 is in Phase 1 clinical development. It is an investigational drug and has not been approved by regulatory authorities. One Phase 1 trial has been completed, which enrolled 9 participants with Hepatitis C.
MK-8876 has been studied in one completed clinical trial, NCT01930058, titled "Safety, Pharmacokinetics, and Pharmacodynamics of MK-8876 in Participants With Hepatitis C Infection (MK-8876-003)." This Phase 1 trial enrolled 9 participants and was controlled but not double-blinded.
MK-8876 is not FDA approved. It is an investigational drug currently in Phase 1 clinical development for Hepatitis C. The completed trial, NCT01930058, was a controlled Phase 1 study, but the drug has not yet received regulatory approval.